Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
Proteomics Clin Appl. 2008 Jul;2(7-8):974-88. doi: 10.1002/prca.200780163. Epub 2008 Jul 10.
We have applied protein expression profiling technologies in combination with immunohistochemistry, using fresh tissue and urine samples, to assess bladder cancer heterogeneity and prognosis as well as to generate protein markers for tumor progression and early diagnosis of the disease. Here, we review some selected lines of investigation and approaches undertaken by our laboratory, drawing on more than 15 years of experience in bladder cancer proteomics, to highlight a number of issues that may be useful for researchers entering the field. In particular, we address the identification of markers for bladder cancer progression and exemplify the potential of gel-based proteomic profiling of urine samples for the early detection of urothelial carcinomas. In addition, we provide a brief description of a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the tumor microenvironment.
我们已经应用蛋白质表达谱分析技术，结合免疫组织化学，使用新鲜组织和尿液样本，来评估膀胱癌的异质性和预后，并为肿瘤进展和疾病的早期诊断生成蛋白质标志物。在这里，我们回顾了我们实验室进行的一些选定的研究路线和方法，借鉴了我们在膀胱癌蛋白质组学领域超过 15 年的经验，强调了一些可能对进入该领域的研究人员有用的问题。特别是，我们确定了膀胱癌进展的标志物，并举例说明了基于凝胶的尿液样本蛋白质组分析在早期检测尿路上皮癌方面的潜力。此外，我们简要描述了一种新的、很有前途的生物标志物来源，即肿瘤间质液（TIF），它灌注肿瘤微环境。
